↓ Skip to main content

Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)

Overview of attention for article published in Expert Review of Pharmacoeconomics and Outcomes Research, April 2023
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
2 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
Published in
Expert Review of Pharmacoeconomics and Outcomes Research, April 2023
DOI 10.1080/14737167.2023.2197213
Pubmed ID
Authors

Medo Gutić, Miloš N. Milosavljević, Teodora Safiye, Ardea Milidrag, Slobodan M. Jankovic

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 2 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 2 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 100%
Readers by discipline Count As %
Unspecified 2 100%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2023.
All research outputs
#7,639,861
of 24,547,718 outputs
Outputs from Expert Review of Pharmacoeconomics and Outcomes Research
#216
of 743 outputs
Outputs of similar age
#132,326
of 404,791 outputs
Outputs of similar age from Expert Review of Pharmacoeconomics and Outcomes Research
#3
of 12 outputs
Altmetric has tracked 24,547,718 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 743 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 404,791 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.